1. Home
  2. DHF vs CHRS Comparison

DHF vs CHRS Comparison

Compare DHF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DHF
  • CHRS
  • Stock Information
  • Founded
  • DHF 1998
  • CHRS 2010
  • Country
  • DHF United States
  • CHRS United States
  • Employees
  • DHF N/A
  • CHRS N/A
  • Industry
  • DHF Finance Companies
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DHF Finance
  • CHRS Health Care
  • Exchange
  • DHF Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • DHF 188.4M
  • CHRS 191.3M
  • IPO Year
  • DHF N/A
  • CHRS 2014
  • Fundamental
  • Price
  • DHF $2.63
  • CHRS $1.30
  • Analyst Decision
  • DHF
  • CHRS Strong Buy
  • Analyst Count
  • DHF 0
  • CHRS 4
  • Target Price
  • DHF N/A
  • CHRS $5.38
  • AVG Volume (30 Days)
  • DHF 451.1K
  • CHRS 1.9M
  • Earning Date
  • DHF 01-01-0001
  • CHRS 03-12-2025
  • Dividend Yield
  • DHF 7.65%
  • CHRS N/A
  • EPS Growth
  • DHF N/A
  • CHRS N/A
  • EPS
  • DHF N/A
  • CHRS N/A
  • Revenue
  • DHF N/A
  • CHRS $304,340,000.00
  • Revenue This Year
  • DHF N/A
  • CHRS $2.47
  • Revenue Next Year
  • DHF N/A
  • CHRS N/A
  • P/E Ratio
  • DHF N/A
  • CHRS N/A
  • Revenue Growth
  • DHF N/A
  • CHRS 44.19
  • 52 Week Low
  • DHF $2.06
  • CHRS $0.66
  • 52 Week High
  • DHF $2.39
  • CHRS $2.87
  • Technical
  • Relative Strength Index (RSI)
  • DHF 59.07
  • CHRS 44.77
  • Support Level
  • DHF $2.53
  • CHRS $1.29
  • Resistance Level
  • DHF $2.64
  • CHRS $1.45
  • Average True Range (ATR)
  • DHF 0.03
  • CHRS 0.12
  • MACD
  • DHF 0.01
  • CHRS -0.03
  • Stochastic Oscillator
  • DHF 88.89
  • CHRS 13.29

About DHF BNY Mellon High Yield Strategies Fund

BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Share on Social Networks: